IP Library Granted Patent US 10,487,134
Granted Patent B2
US 10,487,134 · App. 14/371,161 · Granted Nov 26, 2019

Modified collagen

Inventors: Alexandra Dietrich (Saal/Donau, DE); Michael Myers (Ashburn, VA)
Assignee: INNOCOLL PHARMACEUTICALS LIMITED
C07K14/78A61K31/445A61K31/7036A61K47/42A61L27/24A61L27/54C08L89/00C08L89/06A61K38/39A61L2300/204A61L2300/23A61L2300/402A61L2300/406
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,487,134
App. No.
14/371,161
Granted
Nov 26, 2019
Kind
B2
Abstract

The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Claims (24)

1. A method for manufacturing a composition comprising a modified collagen, the method comprising the steps of:

(a) providing isolated collagen;

(b) freezing the isolated collagen to obtain frozen collagen;

(c) dehydrating the frozen collagen to obtain dehydrated collagen;

(d) maintaining the dehydrated collagen at a temperature of about 40° C. to about 65° C. for a period of at least one week;

(e) preparing an aqueous dispersion of the collagen obtained in step (d);

(f) mechanically degrading the aqueous dispersion; and

(g) dehydrating the aqueous dispersion.

2. The method of claim 1 , wherein the preparing step (e) comprises heating water to about 35° C. to about 42° C. prior to adding to the modified collagen.

3. The method of claim 1 , wherein the providing step (a) comprises providing a dispersion having a concentration of about 3-30% (w/w) collagen particles.

4. The method of claim 1 , wherein the freezing step comprises freezing to a temperature of about −33° C. to about −42° C.

5. The method of claim 1 , wherein the dehydrating step (c) comprises removing the aqueous phase by reducing the pressure to about 0.05 to about 0.5 mbar.

6. The method of claim 1 , wherein the dehydrating step (c) comprises increasing the temperature of the collagen to about +30° C.

7. The method of claim 1 , wherein the dehydrating step (c) comprises at least one equilibrating step, wherein each equilibrating step comprises maintaining the temperature at a constant temperature for at least 10 minutes.

8. The method of claim 1 , wherein the maintaining step is conducted at a temperature of at least 65° C. for a period of at least one week.

9. The method of claim 1 , wherein the maintaining step is conducted at a relative humidity of less than 80%.

10. The method of claim 1 , wherein the maintaining step is conducted for a period of at least two weeks.

11. The method of claim 1 , wherein the maintaining step is conducted for a period of at least four weeks.

12. The method of claim 1 , wherein the maintaining step is conducted for a period of at least six weeks.

13. The method of claim 1 , wherein the maintaining step is conducted at a temperature of a bout 40° C. for a period of at least six weeks.

14. The method of claim 1 , wherein the maintaining step is conducted at a tempera to re of a bout 40° C. for a period of six weeks to six months.

15. The method of claim 1 , wherein the maintaining step is conducted at a temperature of a bout 40° C. for a period of six weeks to two months.

16. The method of claim 1 , wherein the maintaining step is conducted at a temperature of a bout 40° C. and a relative humidity of 75% for a period of at least six weeks.

17. The method of claim 1 , wherein the preparing step (e) comprises preparing an aqueous dispersion of a drug and the collagen obtained in step (d).

Assignments (6)
SECURITY INTEREST Recorded Nov 7, 2023
From: OAKTREE FUND ADMINISTRATION, LLC
To: GURNET FINANCE SA
Reel/Frame 065484/0092 →
SECURITY INTEREST Recorded Feb 24, 2022
From: INNOCOLL PHARMACEUTICALS LIMITED
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059096/0842 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS INSIDE THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 036806 FRAME: 0528. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 8, 2016
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 037739/0093 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS. PREVIOUSLY RECORDED ON REEL 036593 FRAME 0472. ASSIGNOR(S) HEREBY CONFIRMS ASSIGNMENT. Recorded Sep 24, 2015
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 036806/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2015
From: INNOCOLL TECHNOLOGIES LIMITED
To: INNOCOLL PHARMACEUTICALS LIMITED
Reel/Frame 036593/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: DIETRICH, ALEXANDRA; MYERS, MICHAEL
To: INNOCOLL TECHNOLOGIES LIMITED
Reel/Frame 033811/0494 →
Priority Claims (2)
EP 12150527 · Jan 9, 2012 · regional
GB 1220868.2 · Nov 20, 2012 · national
Continuity (1)
Related Publication 20150011476A1 · Jan 8, 2015